Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HBV Reactivation After CAR T-Cell Therapy in DLBCL

Key clinical point: A rare case of severe hepatitis B virus (HBV) reactivation was reported in a patient with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who received chimeric antigen receptor (CAR) T-cell therapy.

Major finding: After HBV reactivation, no clinical improvement was observed, and the patient died of multiple organ dysfunction and hepatic encephalopathy at 40 days post-admission.

Study details: A clinical case report of a 64-year-old woman with relapsed/refractory DLBCL.

Disclosures: The study was supported by the National Natural Science Foundation of China. The authors reported having no conflicts of interest.

Citation:

Wei J et al. J Immunother Cancer. 2019 Nov 21. doi: 10.1186/s40425-019-0790-y.